Pacira BioSciences to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare Conference
Pacira BioSciences (Nasdaq: PCRX) will participate in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on April 15, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Pacira BioSciences (Nasdaq: PCRX) will participate in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on April 15, 2026. Live audio and a replay (available for two weeks) can be accessed via the company events page.
Pacira also granted inducement equity awards on April 2, 2026: stock options aggregating 5,000 shares (10-year term, exercise price $22.70, four-year vesting) and restricted stock units aggregating 13,000 shares (four annual vesting installments beginning April 1, 2027). Awards were approved by the People & Compensation Committee under Nasdaq Rule 5635(c)(4).
Details
News Market Reaction – PCRX
On Apr 8, the day this news came out, PCRX closed 3.20% above the previous close.
Data tracked by StockTitan Argus for the Apr 8 session.
Key Figures
- Stock options granted
- 5,000 shares
- Inducement awards to two employees under 2014 Inducement Plan on Apr 2, 2026
- RSUs granted
- 13,000 shares
- Inducement RSU awards to seven employees on Apr 2, 2026
- Option term
- 10 years
- Term of inducement stock options granted under Inducement Plan
- Vesting period
- 4 years
- Vesting schedule for inducement stock options and RSUs
- Initial vesting tranche
- 25 percent
- Portion of option shares vesting on first anniversary of employment
- Subsequent vesting
- 36 months
- Equal quarterly option vesting over 36 months after first anniversary
- Exercise price
- $22.70 per share
- Closing PCRX price on Nasdaq Global Select Market on grant date
- Fireside chat time
- 9:30 AM ET
- Needham Virtual Healthcare Conference on April 15, 2026
Historical Context
-
Real-world EXPAREL data showed reduced cost of care versus comparators.
-
DOMA Perpetual nominated three director candidates for Pacira’s board.
-
Company reaffirmed shareholder value focus and highlighted 2025 operational metrics.
-
Additional coverage of DOMA’s three director nominations and campaign.
-
Reported Nasdaq Rule 5635(c)(4) inducement equity awards to new employees.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
nasdaq listing rule 5635(c)(4) regulatory
inducement awards financial
stock options financial
restricted stock units financial
vesting schedule financial
exercise price financial
nasdaq global select market regulatory
restricted stock unit financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
BRISBANE, Calif., April 08, 2026 (GLOBE NEWSWIRE) -- Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to deliver innovative, non-opioid pain therapies to transform the lives of patients, today announced that it will participate in an analyst-led fireside chat at the 25th Annual Needham Virtual Healthcare Conference at 9:30 AM ET on Wednesday, April 15, 2026.
Live audio of the virtual event can be accessed by visiting the “Events” page of the company’s website at investor.pacira.com. A replay of the webcast will also be available for two weeks following the event.
Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira today announced the granting of inducement awards on April 2, 2026 to three new employees under Pacira’s Amended and Restated 2014 Inducement Plan (the “Inducement Plan”) as a material inducement to each employee’s entry into employment with the company. In accordance with Nasdaq Listing Rule 5635(c)(4), the awards were approved by the People & Compensation Committee of the Board of Directors (the “Committee”) without stockholder approval.
Two employees received stock options to purchase an aggregate of 5,000 shares of Pacira common stock and seven employees received restricted stock units for an aggregate of 13,000 shares of Pacira common stock. The stock options have a 10-year term and a four-year vesting schedule with 25 percent of the underlying shares vesting on the first anniversary of the recipient’s first day of employment and in successive equal quarterly installments over the 36 months thereafter. The stock options have an exercise price of
Vesting of the equity awards is subject to the employee’s continued employment with Pacira. Each equity award is also subject to the terms and conditions of an award agreement.
About Pacira
Pacira delivers innovative, non-opioid pain therapies to transform the lives of patients. Pacira has three commercial-stage non-opioid treatments: EXPAREL® (bupivacaine liposome injectable suspension), a long-acting local analgesic currently approved for infiltration, fascial plane block, and as an interscalene brachial plexus nerve block, an adductor canal nerve block, and a sciatic nerve block in the popliteal fossa for postsurgical pain management; ZILRETTA® (triamcinolone acetonide extended-release injectable suspension), an extended-release, intra-articular injection indicated for the management of osteoarthritis knee pain; and iovera®º, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve. The company is also advancing a pipeline of clinical-stage assets for musculoskeletal pain and adjacencies, its most advanced product candidate, PCRX-201 (enekinragene inzadenovec), a novel locally administered gene therapy in Phase 2 clinical development for osteoarthritis of the knee. To learn more about Pacira, visit www.pacira.com.

Company Contact: Pacira BioSciences, Inc. Christian Pedetti (973) 254-4387 Christian.pedetti@pacira.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.